지속성 각막 상피 결손(PCED) : 신규 요법, 미충족 수요 및 TPP 인사이트 리포트(2026년)

Persistent Corneal Epithelial Defect (PCED) Emerging Therapy and TPP Insights

Thelansis's "Persistent Corneal Epithelial Defect (PCED) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Persistent Corneal Epithelial Defect (PCED) Overview

Persistent corneal epithelial defect (PCED) is a severe ocular pathology defined by the failure of the corneal epithelium to close within two weeks despite standard management. Resulting from a disrupted regenerative cycle, it stems from neurotrophic keratopathy, limbal stem cell deficiency, chemical burns, or severe ocular surface disease. Left untreated, chronic defects risk stromal melting, perforation, and permanent scarring. Diagnosis relies on slit-lamp biomicroscopy with fluorescein staining, corneal sensitivity tracking, and anterior segment OCT. Foundational management utilizes preservative-free lubrication, therapeutic bandage contact lenses, and low-dose oral doxycycline to inhibit tissue-degrading matrix metalloproteinases. Biologic repair utilizes autologous or allogeneic serum drops, while the recombinant nerve growth factor cenegermin serves as the approved frontline standard specifically for neurotrophic defects. In 2026, non-neurotrophic pathways target mechanical and cellular restoration via pipeline options like lufepirsen ophthalmic gel or secretome drops. Amniotic membrane transplantation or tarsorrhaphy is reserved for refractory cases requiring aggressive closure.

Key Highlights

• In Germany, relapse and refractory Persistent Corneal Epithelial Defect (PCED) cases are projected to increase from 718 patients in 2025 to 827 patients by 2035, reflecting a gradual rise in disease burden.
• Persistent Corneal Epithelial Defect remains a serious ocular surface condition associated with impaired corneal healing, vision loss risk, and recurrent disease progression.
• Increasing awareness, improved ophthalmic diagnostics, and rising prevalence of underlying conditions such as neurotrophic keratitis and diabetes are contributing to higher diagnosis rates.
• Significant unmet need persists in relapse and refractory patients who demonstrate inadequate response to conventional lubricants, bandage contact lenses, and supportive therapies.
• Growing focus on biologics, regenerative therapies, and novel ophthalmic formulations is expected to transform the treatment landscape over the forecast period.
• The global neurotrophic keratitis treatment market is projected to grow at nearly 9% CAGR through 2030, supported by increasing biologic adoption and expanding recognition of rare corneal disorders.

Market Overview

• The Germany Persistent Corneal Epithelial Defect market is projected to grow from USD 23.84 million in 2025 to USD 212.89 million by 2035, indicating strong market expansion.
• Market growth is driven by:
• Increasing diagnosis of refractory and relapse cases
• Rising adoption of advanced biologics and regenerative ophthalmic therapies
• Improved access to specialty eye care and rare disease management
• Market value is supported by premium pricing of innovative therapies and growing demand for treatments capable of accelerating corneal healing and preventing recurrence.
• Emerging therapies targeting corneal regeneration, nerve healing, and epithelial repair are expected to create substantial commercial opportunities in Germany.
• Future growth will depend on the successful adoption of advanced biologics and therapies capable of improving long-term visual outcomes while reducing recurrence rates.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Dompe Farmaceutici S.p.A.
• Glaukos Corporation

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)